Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Replacement therapy for hereditary alpha1-antitrypsin deficiency. A program for long-term administration

A F Barker1, F Siemsen, D Pasley

  • 1Department of Pulmonary and Critical Care Medicine, Oregon Health Sciences University, Portland.

Chest
|May 1, 1994
PubMed
Summary

Long-term intravenous alpha1-antitrypsin (AAT) therapy stabilized lung function in most patients with hereditary AAT deficiency and COPD. The treatment showed a good safety profile with minimal adverse events, suggesting its efficacy for managing this condition.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics of COPD in never-smokers and ever-smokers in the general population: results from the CanCOLD study.

Thorax·2015
Same author

Gaps in using bronchodilators, inhaled corticosteroids and influenza vaccine among 23 high- and low-income sites.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2014
Same author

Exacerbation-like respiratory symptoms in individuals without chronic obstructive pulmonary disease: results from a population-based study.

Thorax·2014
Same author

Restricted spirometry in the Burden of Lung Disease Study.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2012
Same author

Quality of spirometry tests performed by 9893 adults in 14 countries: the BOLD Study.

Respiratory medicine·2011
Same author

Public health aspects of volcanic hazards; Evaluation and prevention of excessive morbidity and mortality due to natural disasters.

Disasters·2010

Area of Science:

  • Pulmonology
  • Genetics
  • Pharmacology

Background:

  • Hereditary alpha1-antitrypsin (AAT) deficiency is a genetic disorder that increases the risk of developing chronic obstructive pulmonary disease (COPD).
  • Intravenous augmentation therapy with AAT is a potential treatment for individuals with AAT deficiency and COPD, aiming to slow disease progression.

Purpose of the Study:

  • To evaluate the long-term efficacy and safety of intravenous AAT administration in patients with hereditary AAT deficiency and COPD.

Main Methods:

  • This study conducted a retrospective chart review of 14 patients diagnosed with hereditary AAT deficiency and COPD.
  • Patients received long-term intravenous AAT therapy over an observation period ranging from 12 to 48 months.

Main Results:

Related Experiment Videos

  • Twelve out of 14 patients experienced stabilization of their functional status during the study period.
  • Pulmonary function remained stable in 13 of 14 patients, and 4 patients showed a reduction in hospitalizations.
  • Three patients reported self-limited adverse reactions to AAT, with one requiring brief hospitalization.

Conclusions:

  • Long-term intravenous AAT therapy appears to be effective in stabilizing functional status and maintaining pulmonary function in patients with hereditary AAT deficiency and COPD.
  • The treatment demonstrated a favorable safety profile with manageable adverse events, supporting its use in this patient population.